

Melbourne, 11 August 2017

Section 708A Cleansing Statement and Appendix 3B

This notice is given by Clean TeQ Holdings Limited (**Company**) under Section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

- (a) the Company has issued 1,637,001 fully paid ordinary shares (**Shares**) at an issue price of \$0.1450 (14.50 cents) per Share in relation to the conversion of unlisted options.
- (b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) section 674 of the Corporations Act as it applies to the Company; and
- (e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

For more information about Clean TeQ contact:

Sam Riggall, Managing Director or Ben Stockdale, CFO

+61 3 9797 6700

About Clean TeQ Holdings Limited (ASX:CLQ) – Based in Melbourne, Clean TeQ, using its proprietary Clean-iX® continuous ion exchange technology, is a leader in metals recovery and industrial water treatment.

For more information about Clean TeQ please visit the Company's website www.cleanteq.com.

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Clean TeQ Holdings Limited

ABN

34 127 457 916

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- ¹ +Class of +securities issued or to be issued
- (a) Fully paid ordinary shares
- (b) Unquoted performance rights
- (c) Unquoted options
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- (a) 1,637,001
- (b) 1,724,254
- (c) 750,000
- 3 Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)
- (a) Fully paid ordinary shares
- (b) Convertible into fully paid ordinary shares on 1:1 basis subject to the terms of the Company's Employee Incentive Plan and meeting service and performance criteria. Vest date 1 July 2020
- (c) Unquoted options exercisable at \$0.77 (77 cents) on or before 17 February 2020

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

Do the +securities rank equally in all 4 respects from the date of allotment with an existing *class of quoted *securities?

> If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution interest payment

- (a) Yes
- (b) No. However fully paid ordinary shares issued pursuant to conversion of performance rights will rank in all in all respects pari passu with existing shares at the date of issue
- (c) No. However fully paid ordinary shares issued pursuant to conversion of unlisted options will rank in all respects pari passu with existing shares at the date of issue

- Issue price or consideration 5
- (a) \$237,365.14
- (b) Nil
- (c) Nil
- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets
- (a) Conversion of unlisted options exercisable at \$0.1450 (14.50 cents)
- (b) Issue of performance rights to eligible employees and Directors as part of the Company's Employee Incentive Plan, as approved by shareholders on 19 July 2017
- (c) Issue of options to eligible Directors as part of the Company's Employee Incentive Plan, as approved by shareholders on 19 July 2017
- 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

- 6b The date the security holder resolution under rule 7.1A was passed
- Number of *securities issued without | Nil 6c security holder approval under rule 7.1
- 6d Number of *securities issued with security holder approval under rule 7.1A

Yes

22 November 2016

Nil

Appendix 3B Page 2 01/08/2012

⁺ See chapter 19 for defined terms.

| 6e | securit or an | er of *securities issued with y holder approval under rule 7.3, other specific security holder al (specify date of meeting) | (b) 411,546 unquoted performance rights – 19 July 2017 (c) 750,000 unquoted options – 19 July 2017 | |
|----|---------------------------------|--|---|-----------------------------------|
| 6f | | er of securities issued under an ion in rule 7.2 | (a) 1,637,001 fully paid ordinary shares (b) 1,312,708 unquoted performance rights | |
| 6g | issue p as calcu the issu | rities issued under rule 7.1A, was rice at least 75% of 15 day VWAP ulated under rule 7.1A.3? Include ue date and both values. Include irce of the VWAP calculation. | N/A | |
| 6h | for not on whi | rities were issued under rule 7.1A n-cash consideration, state date ch valuation of consideration was d to ASX Market Announcements | N/A | |
| 6i | capacit comple | ate the entity's remaining issue by under rule 7.1 and rule 7.1A – tete Annexure 1 and release to ASX to Announcements | LR 7.1 82,595,463 LR 7.1A 57,796,976 TOTAL 140,392,439 | |
| 7 | | of entering *securities into ificated holdings or despatch of tate | 11 August 2017 | |
| | | | | Lia |
| 8 | quoted | er and ⁺ class of all ⁺ securities l on ASX (<i>including</i> the securities ion 2 if applicable) | Number 577,969,756 | +Class Ordinary fully paid shares |
| | | | | |
| 9 | quoted | er and +class of all +securities not l on ASX (<i>including</i> the securities | 42,374,769 | Options over ordinary shares |
| | in secti | ion 2 if applicable) | 6,602,183 | Performance Rights |
| 10 | distrib | nd policy (in the case of a trust, ution policy) on the increased (interests) | N/A | |
| | Part 2 - Bonus issue or pro rat | | ta issue | |
| | 11 | Is security holder approva- required? | l N/A | |
| | | | | |
| | 12 | Is the issue renounceable or non-renounceable? | N/A | |

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

| 13 | Ratio in which the *securities will be offered | N/A |
|----|---|-----|
| 14 | ⁺ Class of ⁺ securities to which the offer relates | N/A |
| 15 | ⁺ Record date to determine entitlements | N/A |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | N/A |
| 17 | Policy for deciding entitlements in relation to fractions | N/A |
| 18 | Names of countries in which the entity has *security holders who will not be sent new issue documents | N/A |
| | Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. | |
| | Closs reference. Tule 7.7. | |
| 19 | Closing date for receipt of acceptances or renunciations | N/A |
| 20 | Names of any underwriters | N/A |
| 21 | Amount of any underwriting fee or commission | N/A |
| 22 | Names of any brokers to the issue | N/A |
| 23 | Fee or commission payable to the broker to the issue | N/A |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders | N/A |

Appendix 3B Page 4 01/08/2012

⁺ See chapter 19 for defined terms.

| 25 | If the issue is contingent on +security holders' approval, the date of the meeting | N/A |
|----|---|-----|
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled | N/A |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | N/A |
| 28 | Date rights trading will begin (if applicable) | N/A |
| 29 | Date rights trading will end (if applicable) | N/A |
| 30 | How do *security holders sell their entitlements <i>in full</i> through a broker? | N/A |
| 31 | How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | N/A |
| | | |
| 32 | How do *security holders dispose of their entitlements (except by sale through a broker)? | N/A |
| 33 | ⁺ Despatch date | N/A |
| | | |

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

Type of securities (*tick one*)

(a) Securities described in Part 1

⁺ See chapter 19 for defined terms.

| New issue announcement | | |
|------------------------|--|--|
| (b) | All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertib securities | |
| Entitie | s that have ticked box 34(a) | |
| | onal securities forming a new class of securities indicate you are providing the information or ents | |
| 35 | If the *securities are *equity securities, the names of the 20 largest holders of th additional *securities, and the number and percentage of additional *securities held by those holders | |
| 36 | If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 100,000 10,001 - 100,000 100,001 and over | |
| 37 | A copy of any trust deed for the additional *securities | |
| Entitie | s that have ticked box 34(b) | |
| 38 | Number of securities for which †quotation is sought | |

Class of *securities for which

quotation is sought

39

Appendix 3B

Appendix 3B Page 6 01/08/2012

⁺ See chapter 19 for defined terms.

| 40 | Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not | | |
|----|--|--------|--------|
| | rank equally, please state: 1. the date from which they do 2. the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment 3. the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | | |
| 41 | Reason for request for quotation now | | |
| | Example: In the case of restricted securities, end of restriction period | | |
| | (if issued upon conversion of another security, clearly identify that other security) | | |
| | | | |
| 42 | Number and *class of all *securities quoted on ASX (including the securities in clause 38) | Number | +Class |
| | | | |

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here Date: 11 August 2017

(Company secretary)

Print name: Melanie Leydin

== == == ==

Appendix 3B Page 8 01/08/2012

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for *eligible entities

Introduced 01/08/12

Part 1

| Rule 7.1 – Issues exceeding 15% of capital | | |
|---|---|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | |
| Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue | 439,252,097 | |
| Add the following: | | |
| Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 | 33,000 – 23 August 2016 500,000 – 26 August 2016 38,461,539 – 8 November 2016 | |
| Number of fully paid ordinary securities issued in that 12 month period with shareholder approval | 553,155 - 17 February 2017 577,800 – 14 March 2017 | |
| Number of partly paid ordinary securities that became fully paid in that 12 month period | 135,251 – 23 March 2017 92,518,888 – 27 March 2017 | |
| Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | 100,000 – 21 April 2017 600,000 – 5 May 2017 288,745 – 5 June 2017 3,211,255 – 9 June 2017 34,580 – 20 June 2017 66,445 – 28 July 2017 1,637,001 – 11 August 2017 | |
| Subtract the number of fully paid ordinary securities cancelled during that 12 month period | - | |
| "A" | 577,969,756 | |

⁺ See chapter 19 for defined terms.

| Step 2: Calculate 15% of "A" | | | |
|---|--|--|--|
| "B" | 0.15 [Note: this value cannot be changed] | | |
| Multiply "A" by 0.15 | 86,695,463 | | |
| Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used | | | |
| Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued: Under an exception in rule 7.2 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | 500,000 – 19 December 2016 3,000,000 – 27 February 2017 600,000 – 20 June 2017 | | |
| "C" | 4,100,000 | | |
| Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1 | | | |
| "A" x 0.15 Note: number must be same as shown in Step 2 | 86,449,913 | | |
| Subtract "C" Note: number must be same as shown in Step 3 | 4,100,000 | | |
| <i>Total</i> ["A" x 0.15] – "C" | 82,595,463 [Note: this is the remaining placement capacity under rule 7.1] | | |

Appendix 3B Page 10 01/08/2012

⁺ See chapter 19 for defined terms.

Part 2

| Rule 7.1A – Additional placement capacity for eligible entities | | | |
|--|---|--|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | | |
| "A" Note: number must be same as shown in Step 1 of Part 1 | 577,969,756 | | |
| Step 2: Calculate 10% of "A" "D" | 0.10 Note: this value cannot be changed | | |
| Multiply "A" by 0.10 | 57,796,976 | | |
| Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used | | | |
| Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items | - | | |

⁺ See chapter 19 for defined terms.

| Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A | | |
|---|--|--|
| "A" x 0.10 Note: number must be same as shown in Step 2 | 57,796,976 | |
| Subtract "E" Note: number must be same as shown in Step 3 | - | |
| <i>Total</i> ["A" x 0.10] – "E" | 57,796,976 Note: this is the remaining placement capacity under rule 7.1A | |

Appendix 3B Page 12 01/08/2012

⁺ See chapter 19 for defined terms.